호르몬 피임약 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Hormonal Contraceptives Market size is expected to reach USD 79.50 Billion in 2034 from USD 38.82 Billion (2025) growing at a CAGR of 8.29% during 2026-2034.

The Global Hormonal Contraceptives Market is expanding steadily as awareness of family planning and reproductive health increases worldwide. Hormonal contraceptives, including pills, injections, patches, and implants, are widely used to prevent pregnancy and manage reproductive health conditions. Rising female workforce participation, improved access to healthcare, and increased government initiatives supporting reproductive health are driving market growth.

Market drivers include continuous advancements in contraceptive formulations that improve safety, effectiveness, and convenience. Increasing education about reproductive health and the availability of diverse contraceptive options are encouraging adoption. Pharmaceutical companies are also investing in research to develop long-acting and user-friendly hormonal contraceptive methods, further expanding the market.

Future growth is expected to be driven by expanding healthcare infrastructure and growing awareness in developing regions. Innovations in hormone delivery systems and digital health integration for contraceptive management will further support adoption. However, side effects, cultural barriers, and regulatory challenges may limit market penetration in certain regions. Despite these challenges, the market is poised for sustained growth due to rising awareness and evolving healthcare practices.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product

• Pills
• Skin Patches
• Intrauterine Devices
• Hormonal Implants
• Vaginal Rings
• Others

By Hormone

• Progestin Only
• Combined Hormone Contraceptives

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Bayer AG, Pfizer Inc, Merck Co Inc, Johnson Johnson, AbbVie Inc, GlaxoSmithKline plc, Mylan NV, Teva Pharmaceutical Industries Ltd, Novartis AG, HRA Pharma, Mithra Pharmaceuticals, Celgene Corporation
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HORMONAL CONTRACEPTIVES MARKET: BY PRODUCT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product
• 4.2. Pills Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Skin Patches Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Intrauterine Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Hormonal Implants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Vaginal Rings Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HORMONAL CONTRACEPTIVES MARKET: BY HORMONE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Hormone
• 5.2. Progestin Only Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Combined Hormone Contraceptives Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HORMONAL CONTRACEPTIVES MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HORMONAL CONTRACEPTIVES MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product
  • 7.2.2 By Hormone
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product
  • 7.3.2 By Hormone
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product
  • 7.4.2 By Hormone
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product
  • 7.5.2 By Hormone
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product
  • 7.6.2 By Hormone
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL HORMONAL CONTRACEPTIVES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Bayer AG
  • 9.2.2 Pfizer Inc
  • 9.2.3 Merck & Co. Inc
  • 9.2.4 Johnson & Johnson
  • 9.2.5 AbbVie Inc
  • 9.2.6 GlaxoSmithKline Plc
  • 9.2.7 Mylan N.V
  • 9.2.8 Teva Pharmaceutical Industries Ltd
  • 9.2.9 Novartis AG
  • 9.2.10 HRA Pharma
  • 9.2.11 Mithra Pharmaceuticals
  • 9.2.12 Celgene Corporation